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Abstract
Background: Cisplatin is a commonly used chemotherapeutic agent that has a major limitation because of its
nephrotoxicity. We have demonstrated that cisplatin down-regulates the expression of the taurine transporter gene
(TauT) in renal cells and that forced overexpression of TauT protects against cisplatin-induced apoptosis in renal
cells in vitro and in vivo. In the present study, we have investigated how TauT is regulated by p53 and c-Jun and
its role during acute kidney injury (AKI).
Methods: Regulation of TauT by p53 and c-Jun was determined by reporter gene assay, DNA binding, Western
blot analysis, and immunohistochemistry.
Results: TauT was down-regulated by p53 and up-regulated by c-Jun. Two potential binding sites for c-Jun were
identified in the promoter region of TauT. Inhibition of c-Jun N-terminal kinase (JNK) enhanced TauT promoter
activity. Overexpression of TauT protects against cisplatin-induced kidney injury in a TauT transgenic mouse model.
Conclusions: Our findings suggest that TauT plays a critical role in renal function. Expression of TauT is negatively
regulated by p53 and positively regulated by c-Jun, which is mediated by the JNK signaling pathway. The outcome
level of TauT may determine the fate of renal cells during stress-induced AKI.
Background
Acute kidney injury due to ischemic or toxic renal injury
is a common disorder with a mortality of about 50%
[1,2]. A vast majority of research in the field has focused
on the determination of events and factors that cause
renal proximal tubular cell (RPTC) injury and death and
lead to the development of AKI. Cisplatin-induced AKI is
currently a topic of intense study. As a highly effective
chemotherapeutic agent, cisplatin has been used to treat
a wide variety of solid tumors [3]. However, 25-35% of
patients experience a significant decline in renal function
after the administration of a single dose of cisplatin [4].
Several mechanisms, including oxidation, inflammation,
genotoxic damage and cell cycle arrest, have been impli-
cated in cisplatin nephrotoxicity [5-10]. The JNK (c-Jun
N-terminal kinase) pathway is a major stress signaling
pathway in cells that plays important roles in many cellu-
lar processes, including development, apoptosis, cell
growth and immune responses [11,12].
Recently, the mechanisms of renal cell repair and
regeneration have garnered much attention [7]. Unfortu-
nately, the development of therapeutic strategies that are
efficacious in humans with AKI has proven problematic.
This suggests that the development of more successful
therapies requires approaching the problem from a dif-
ferent vantage point [1]. The regenerative capacity of
the kidney is well documented [2], and the responses of
surviving RPTC are thought to be crucial to the restora-
tion of renal function following AKI. Consequently,
identifying genes that are involved in RPTC protection,
repair, and regeneration may uncover new therapeutic
targets that promote renal recovery and decrease the
severity of AKI.
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Cell culture
MDCK kidney cells were cultured according to AATC
(American Association Tissue Culture) guidelines.
Briefly, cells were grown as confluent monolayers in 10
cm diameter tissue culture plates in DMEM media spe-
cific for each cell line with 10% fetal calf serum at 37°C
i nt h ep r e s e n c eo f5 %C O 2 in a humidified incubator.
Cells were plated 18 h before transfection and fed with
fresh medium 4 h before transfection.
Construction of the reporter gene
The promoter region of TauT was identified in previous
studies [13], and a p53-binding consensus site was
found in the TauT promoter sequence, located at -663
to -695. In this study, ~1.1 kb of the TauT promoter
region DNA was used as the template for PCR (Gen-
Bank
TM/EBI accession number AR151716) and the PCR
fragment was cloned into the promoter-less luciferase
vector pGL3-Basic (Promega, Madison, WI) to generate
the plasmid p963 for use in transfections and luciferase
assays. The conditions used were 30 cycles of 1 min of
denaturation at 94°C, 1 min of annealing at 58°C,
and 1 min of elongation at 72°C. The sense primer (5′-
GGGGTACCTTACTGAAGGTCACACAGC-3′)d e s i g -
ned for PCR contained a unique site for KpnI, and the
antisense primer (5′-AAGATCTTGGCACGGGAG
TTCA-3′)c o n t a i n e dau n i q u es i t ef o rB g l I I .P C Rp r o -
ducts were digested with KpnI and BglII and re-ligated
into KpnI and BglII sites of pGL3-Basic to generate
plasmids containing segments of the TauT promoter
sequence extending from the +48 nucleotide corre-
sponding to the transcriptional start site. The constructs
were verified by DNA sequencing. The p53-binding site
deletion (del pGL-563) and p53 mutation (mt pGL-963)
constructs were generated from the p963 plasmid by
using sense primers 5′-GGGGTACCGAGTTGGG-
GAGGGA-3′,a n d5 ′-GGGGTACCAGATGAGG-AAA
CCCCCACACAGAAGGTCTGGGGCTTGCCTGAT
GTCA-3′, respectively. The antisense primer used for
these constructs was the same as described above.
Transient transfection
Plasmid DNA was introduced into cultured MDCK cells
using cationic liposomes (LipofectAMINE). Transfection
was carried out for 16-18 h, and then cells were washed
twice with phosphate-buffered saline and incubated in
fresh medium for 24-48 h before harvesting. pGL-con-
trol, which contains a luciferase gene driven by the
SV40 early region promoter/enhancer, and empty pGL-
Basic vectors were used as positive and negative
controls, respectively. To standardize the transfection
efficiency, 0.1 µg of pRL-CMV vector (pRL Renilla
reniformis luciferase control reporter vector; Promega)
was cotransfected in all experiments. Cells were har-
vested 48 h after transfection and lysed in 200 µl of
reporter lysis buffer (Promega). A luciferase assay was
performed using a dual luciferase assay kit (Promega),
and activity was measured with an Optocomp 1 lumin-
ometer (MGM Instruments, Inc., Hamden, CT). Promo-
ter activity (mean ± S.D. of four samples in relative light
units) of each construct is represented by relative light
output normalized to pRL-CMV control. Graphs repre-
sent typical results of four separate experiments. The
concentration of protein in the cell extracts was deter-
mined using the Bradford method (Bio-Rad, Hercules,
CA).
Measurement of taurine transport
Taurine transport studies were performed on confluent
monolayers three days after seeding cells. Briefly, cells
were washed with Earle’s Balanced Salt Solution (EBSS)
at 37°C. Uptake was initiated by the addition of uptake
buffer (2 mM KCl, 1 mM MgCl2, 96 mM NaCl, 1.8 mM
CaCl2, 5 mM Hepes, pH 7.6) to which 50 µM unlabeled
taurine and 0.5 µCi/ml
14C-taurine (Perkin Elmer, Bos-
ton, MA) were added. After incubation for 30 min at
room temperature, uptake was terminated by the
removal of uptake buffer followed by three rapid washes
with cold EBSS. Cells were solubilized in 1% SDS in 0.2
N NaOH and radioactivity was counted in a Packard
2000-CA Liquid Scintillation Analyzer.
In vivo model of cisplatin-induced AKI
Male mice (wild-type and TauT transgenic), 10-12
weeks old and weighing 28 to 30 g, were assigned to
treatment groups (n = 8/group). For the experiment,
eight TauT transgenic mice and eight wild-type mice
r e c e i v e das i n g l ed o s eo fc i s p l a t i n( 1 5m g / k gb o d y
weight) by intraperitoneal injection. Eight saline-injected
mice were used as controls. To determine cisplatin-
induced nephrotoxicity, mice were sacrificed three days
after cisplatin injection. Kidney samples were collected
and treated in 10% buffered formalin until used.
Western blot analysis
Cells were lysed in 50 µl M-PER mammalian protein
extraction reagent (Pierce, Inc., Rockford, IL) supple-
mented with a protease inhibitor cocktail for use with
mammalian cell and tissue extracts (Sigma). The lysates
were cleared by centrifugation at 14,000 x g for 2 min,
and the supernatants were transferred to clean tubes.
Equal amounts of protein (50 µg) were separated by
electrophoresis on a 12% SDS-polyacrylamide gel and
transferred to a nitrocellulose membrane (Millipore,
Bedford, MA) using a semi-dry electrophoretic transfer
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nonfat dry milk in Tris base/sodium chloride (TBS) buf-
fer with 0.2% Tween 20 (TBST) at 4°C overnight. The
membranes were incubated with primary antibodies for
1 h at room temperature. Blots were washed with TBST
and incubated with horseradish peroxidase-linked sec-
ondary antibody (Sigma) for another hour, and then
proteins of interest were detected using a chemilumines-
cence detection kit (Pierce, Inc.).
Immunohistochemistry
Immunohistochemistry was performed by following the
manufacturer’s instructions (Pierce). Briefly, samples
were rehydrated in decreasing ethanol series (100%,
95%, and 70%) for 5 min each. Samples were immersed
in 1x PBS for 5 min at room temperature, then quench-
ing solution (3% H2O2 in methanol) for 5 min, and then
washed twice in dH2O for 10 min. Slides were blocked
for 20 min with the blocking buffer. Primary antibodies
(antibody against taurine transporter protein) were
applied to slides and incubated for 1 h. Slides were
washed for 10 min with PBS, then the biotinylated sec-
ondary antibody was applied and incubated for 1 h.
A f t e rw a s h i n gf o r1 0m i nw i t hP B S ,A B Cr e a g e n tw a s
applied for 30 min. Finally, immunostaining was
detected by using a Metal Enhanced DAB Substrate Kit
(Pierce).
Assessment of apoptosis
Apoptotic cells in kidney sections were detected by the
terminal deoxynucleotidyl transferase (TdT)-mediated
digoxigenin-deoxyuridine nick-end labeling (TUNEL)
method following the manufacturer’s instructions (R&D
Systems, Minneapolis, MN).
Statistics
All experiments were performed in triplicate. Luciferase
assays are expressed in units of relative light output.
The data represent the mean ± standard error of three
or four experiments. Statistical comparisons were made
using one-way analysis of variance and Student’s t test
to determine significant differences in the means.
Results
TauT is directly regulated by c-Jun in renal cells
Our studies have shown that TauT is regulated by sev-
eral transcription factors, including Sp1, WT1, and p53
[14-16]. Figure 1 depicts the promoter region of TauT
and the locations of potential binding sites for indicated
transcription factors. Accordingly, several consensus
Figure 1 TauT promoter sequence and potential binding sites for indicated transcription factors.
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region. To determine the role of c-Jun in TauT expres-
sion, reporter genes were constructed and transiently
transfected into MDCK kidney cells. As shown in Figure
2A, co-transfection of c-Jun enhanced TauT promoter
activity (pGL3-963). Deletion of the site at -647 reduced
the effect of c-Jun, and the effect was totally abolished
when both -647 and -391 sites were mutated (Figure 2B
&2C). Electrophoretic mobility shift assays showed that
a strong c-Jun binding band was detected when both
AP1 sites were presented in the probe. Deletion of the
-647 site reduced abundance of the band (lane 3).
Double deletion of AP1 sites abolished binding of c-Jun
to the TauT promoter (lane 4, Figure 2D).
Osmoregulation of TauT is negatively regulated by JNK
To determine if JNK signaling is involved in osmoregu-
lation of TauT, MDCK kidney cells were cultured in
hypertonic medium (500 mosmol/kg) in the presence of
JNK inhibitor SP600125 or negative control 420123 for
24 hours. MDCK cells cultured in normal medium were
used as control. Expression of TauT was measured by
taurine uptake and reporter gene expression. We found
that taurine uptake was significantly increased in cells
Figure 2 TauT is directly regulated by c-Jun. Reporter genes were transiently transfected in MDCK cells co-transfected with or without c-Jun
for 24 h, and then the luciferase assay was performed on cell lysates. A. Reporter gene pGL3-963, which contains two AP1 sites; B. Reporter
gene pGL3-525, which contains one AP1 site; C. Reporter gene with double mutation of AP1 sites; D. Electrophoretic mobility shift assays were
done using radiolabelled TauT oligonucleotides with nuclear extracts from Rat I cells expressing c-Jun. Lane 1 - control; lane 2 - wt TauT
promoter DNA; lane 3 - single AP1 site deletion; and lane 4 - double AP1 site deletion. *p < 0.01 vs control.
Han and Chesney Journal of Biomedical Science 2010, 17(Suppl 1):S28
http://www.jbiomedsci.com/content/17/S1/S28
Page 4 of 8cultured in hypertonic medium. Inhibition of JNK by
SP600125 further enhanced taurine uptake (Figure 3A).
A similar result was observed in the reporter gene ana-
lysis in these cells (Figure 3B), suggesting that TauT was
negatively regulated by JNK during hypertonic stress.
TauT protects against cisplatin-induced AKI by blocking a
p53-dependent pathway
Kidney tissues were examined by immunohistochemis-
try. As shown in Figure 4A, kidney tissue from TauT
transgenic mice showed stronger immunostaining for
TauT protein (TauT) and taurine as compared to that
from wild-type (wt) mice. TauT and taurine were mainly
found in the S3 segment of proximal tubule cells in nor-
mal wt animals, while TauT and taurine were also
detected in the outer cortex stripe of TauT transgenic
mice.
In saline-treated mice, p53 was detected in both proxi-
mal and distal tubular cells. Treatment with cisplatin
increased expression of p53 to a similar degree in kid-
neys of both wt and transgenic animals. Cisplatin-
induced activation of p53 down-regulated expression of
TauT in the kidney from both wt and TauT transgenic
mice, which in turn greatly reduced levels of intracellu-
lar taurine in the kidneys of both wt and TauT trans-
genic mice. However, both TauT and taurine were
undetectable in cisplatin-treated wt mouse kidney, while
signals of immunostaining for TauT and taurine in cis-
platin-treated transgenic mouse kidney were still
relatively high. In addition, expression of PUMA (p53-
upregulated modulator of apoptosis) was also found in
both proximal and tubular cells, and was elevated in
both groups after cisplatin treatment. Interestingly,
strong signals of immunostaining for PUMA were
observed in the proximal tubules of the ourter cortex
stripe, where vast apoptosis was observed in cisplatin-
treated wt mice but not in cisplatin-treated TauT trans-
genic mice. We have also found that signals of immu-
nostaining for FasL were higher in cisplatin-treated wt
mice, which mainly co-located with p53 and PUMA in
the outer stripe of kidney cortex, while FasL was only
detected in the kidney medulla of TauT transgenic mice
(Figure 4B). Moreover, TUNEL assay revealed clear evi-
dence of cell death in proximal tubules of the cortex
outer stripe (Figure 4C) of kidneys from cisplatin-treated
wt mice, whereas few numbers of TUNEL-positive tubu-
lar epithelial cells were detected in the kidneys of cispla-
tin-treated TauT transgenic mice. Taken together, these
results strongly suggest that TauT plays a critical role in
protecting against cisplatin-induced AKI, possibly
through blocking the p53-dependent pathway.
Discussion
Studies have shown that TauT is regulated by variety of
stresses, including tonicity, oxidation, DNA damage, and
dietary manipulation [17-20], suggesting that TauT is a
stress response gene. However, there are little data avail-
able about signaling pathway(s) that may be involved in
stress-induced TauT regulation. In the present study we
have demonstrated that TauT is a target of c-Jun. c-Jun
binds to two AP1 consensus sites in the TauT promoter
and up-regulates TauT expression in renal cells. Muta-
tion of AP1 sites blocked binding of c-Jun to the TauT
promoter and further abolished the effect of c-Jun on
Figure 3 Osmoregulation of TauT is mediated by JNK signaling
pathway. MDCK cells were cultured in DMEM medium and treated
with 0 or 500 mosmol/kg JNK inhibitor SP600125 or negative
control 420123 for 24 h. A. Taurine uptake; B Reporter gene assay.
*p < 0.05 vs isotonic control; **p < 0.01 vs isotonic control.
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expression of TauT as determined by taurine uptake is
increased by SP600125, an inhibitor of JNK. It is possi-
ble that, binding of taurine to the transporter may con-
tribute to the uptake result, which in turn may also
indirectly indicate an increase of TauT on the cell mem-
brane. Taken together, our results suggest that the JNK
signaling pathway is involved in the osmoregulation of
TauT during hypertonic stress.
The JNK pathway is a major stress signaling pathway
in cells that play important roles in many cellular pro-
cesses, including development, apoptosis and cell
growth. In non-stressed cells, JNK targets the ubiquiti-
nation and subsequent degradation of bound proteins
Figure 4 Immunohistochemistry study of kidney tissues from wild-type and TauT transgenic mice with or without cisplatin treatment.
A. Immunostaining for p53, TauT protein, taurine, PUMA, and FasL (B) was performed on kidney tissue slides using specific antibodies against
the indicated proteins as described in the Methods. C. TUNEL assay was performed on kidney tissue slides using a TACS TdT DAB in situ
apoptosis detection kit (R&D system). Results represent three separate experiments (n=6). Magnification: A x 200, B (top) x 40 and (bottom) x
400, and C x 400.
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with and degrades p53 [22]. However, in stressed cells,
JNK phosphorylates and activates associated c-Jun and
p53 proteins and enhances their transcriptional regula-
tion of stress-responsive genes [23,24]. Our previous
studies have shown that TauT is a target gene of p53.
Activation of p53 by a chemotherapeutic agent (cispla-
tin) suppresses TauT expression both in vitro and in
vivo [18,25]. In the present study, we have further
demonstrated that treatment with cisplatin increased
expression of p53 to a similar degree in kidneys of both
wt and transgenic mice. Cisplatin-induced p53 activation
repressed TauT to an undetectable level, which in turn
resulted in the depletion of taurine in the kidneys of
wild-type mice. However, the levels of TauT and taurine
in the kidneys of cisplatin-treated TauT transgenic mice
are similar to those in the kidneys of normal control
animals. Activation of p53 induced PUMA expression in
both wt and TauT transgenic mice, although elevated
levels of FasL were only observed in the kidneys of wt
mice after cisplatin treatment. These findings suggest
that relatively normal levels of TauT and/or taurine are
able to protect against cisplatin-induced AKI.
Based on these results, we propose a model for p53/c-
Jun-mediated regulation of the TauT gene (Figure 5).
Normally, both p53 and c-Jun bind to the TauT promo-
ter and compete to regulate TauT. Therefore, the level
of TauT protein is tightly regulated by p53 and c-Jun
via the JNK signaling pathway. In stressed cells, JNK
phosphorylates and activates c-Jun and p53 proteins and
enhances their transcriptional regulation of TauT.C i s -
platin-induced activation of p53 decreases TauT promo-
ter activity via the p53-inhibited JNK-c-Jun pathway by
competing with c-Jun for activation. Upon survival sig-
naling, c-Jun substitutes for p53 function and enhances
TauT expression. However, mechanisms of TauT
regulation by p53/JNK-c-Jun pathway during stress-
induced kidney injury remain to be determined.
Conclusions
In the present study, we have shown that expression of
TauT is negatively regulated by p53 and positively regu-
lated by c-Jun, which is likely mediated by the JNK sig-
naling pathway. Both p53 and c-Jun bind to and
compete to regulate TauT. The ultimate level of TauT
expression may determine the fate of renal cells during
stress-induced AKI.
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